Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer
1997

Outpatient Treatment for Small-Cell Lung Cancer

Sample size: 70 publication Evidence: moderate

Author Information

Author(s): H Gogas, FJ Lofts, TRJ Evans, FJC Millard, R Wilson, JL Mansi

Primary Institution: St George's Hospital, London

Hypothesis

To assess the efficacy and toxicity of an outpatient combination chemotherapy in small-cell lung cancer (SCLC).

Conclusion

Epirubicin and etoposide is an active and well-tolerated outpatient regimen for treating SCLC, although survival data were disappointing.

Supporting Evidence

  • Overall response rate was 64.4%, with 23.7% complete responses.
  • Median survival was 10.5 months for limited disease and 7 months for extensive disease.
  • 79% of patients with shortness of breath reported symptom improvement.

Takeaway

Doctors gave medicine to help people with a type of lung cancer, and many felt better, but not everyone lived longer.

Methodology

Patients received epirubicin and etoposide at specified doses for a maximum of six cycles, with evaluations for response and toxicity.

Potential Biases

The results may be affected by the inclusion of unselected patients with varying health statuses.

Limitations

The study included patients with poor prognostic features and did not universally apply thoracic irradiation.

Participant Demographics

Median age was 64 years, with a male-female ratio of 42:28, and 50% had metastatic disease.

Statistical Information

P-Value

0.02

Confidence Interval

CI 52-76.8%

Statistical Significance

p=0.02

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication